drugset / Trial / NCT06119490
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis
Timeline
- Start
- 2023-07-05
- Primary completion
- 2026-07
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abrocitinib | Small molecule | 200 mg | — |
| Subject | Tofacitinib | Small molecule | 10 mg | — |
| Background | Methylprednisolone | Other / unclassified | 1 mg/kg | Intravenous |